The implications of the world’s largest collaborative biological project in the year 2000—the Human Genome Project-combined with the Big Data revolution in the medical sciences holds out tremendous promise for human health. Recognizing the imminent need for the next generation of bioinformatics and genomics tools, four academic entrepreneurs from the prestigious Indian Institute of Science co-founded Strand Genomics Inc. (Strand). “Our focus is on personalized clinical genomics and molecular diagnostics. To address the grand challenge of the “$1000 genome and million dollar interpretation”, we have developed a clinical genomics interpretation and reporting platform, StrandOmics,” says Vijay Chandru, Ph.D, Co-founder, Chairman and CEO, Strand.
Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds under development that target the SF3B1 gene.
Inside sources reveal that Indian pharmaceutical generics firm Lupin, along with other U.S. pharma firms, is considering bidding for GlaxoSmithKline’s auctioned mature and generic drugs.
GSK seeks to divest its lineup of mature drugs in an effort to improve its growth profile by getting rid of its off-patent drugs in North America and Western Europe. The drugs are estimated to bring in annual sales of 1 billion pounds and are expected to fetch two to three times the price on the auction block.
GSK has submitted an application for the world’s first malaria vaccine to the European Medicines Agency (EMA).
The vaccine candidate, RTS,S, is produced in yeast cells and targets the Plasmodium falciparum malaria parasite, most common in sub-Saharan Africa. It uses GSK’s proprietary AS01 adjuvant system, containing QS-21 Stimulon adjuvant licensed from Antigenics, a subsidiary of Agenus, as well as monophosphoryl lipid A (MPL) and liposomes.
Pfizer’s bid to get AstraZeneca has turned out to have a silver lining.
Dr Jane Osbourn, who runs MedImmune’s operations at Granta Park, told me: “It has gelled the team together at AstraZeneca and MedImmune (which is owned by AZ), and this is a silver lining to what has happened.
Out of the roughly 2 million Americans suffering from degenerative heart disease, only about 50,000 of them receive life-saving mitral valve surgery. This is primarily because the most common treatment, an open-heart procedure, can last between three and six hours and is extremely complex and high-risk.
Maryland-based Harpoon Medical plans to revolutionize that process with a new device that could reduce the procedure to just 60 minutes. Using their device, a patient’s chest would remain closed and the heart would continue beating during the procedure. It would cut recovery time from weeks to days and reduce risk factors significantly.
Advaxis, Inc. ADXS +2.08% , a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer.
Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body’s own immune system to help fight cancer. MEDI4736 is designed to counter the tumour’s immune-evading tactics by blocking a signal that helps tumours avoid detection, while ADXS-HPV enhances the ability of immune cells to combat the tumour. Preclinical evidence suggests that the combination of ADXS-HPV with a checkpoint inhibitor, such as MEDI4736, can enhance overall anti-tumour response.
Holy Cross Germantown Hospital is moving closer to opening, forming an inaugural medical staff and ramping up orientation for those new hires, officials said Tuesday.
When the hospital opens Oct. 1, it will have about 580 people working on site, said spokeswoman Yolanda Gaskins. Already, a few Holy Cross Germantown hospital senior managers have begun working at the location using on-site trailers as offices, she said. The $202 million, 93-bed hospital on the campus of Montgomery College in Germantown will be the first new Montgomery County hospital in 35 years.
Montgomery County plans to launch a major technology initiative in its public schools in August, providing 40,000 laptops and tablets to students as part of a project that will expand quickly in coming years, officials said Thursday.
Infectious diseases, pathogens and bioterrorism agents are all inside a new building downtown. Jessica Kartalija explains it’s great news for researchers at Johns Hopkins. It’s the newest addition to the Baltimore Science and Technology Park at Johns Hopkins. Inside, it’s a state-of-the-art lab that will keep Maryland on the cutting edge of public health and technology.
The Intellectual Property Owners (IPO) recently published a list of the top 100 universities worldwide granted U.S. patents in 2013, and among them were three local schools: Johns Hopkins University, the University of Maryland and the University of Virginia.
Apollo Hospitals today announced a partnership with Strand Life Sciences to launch the latter’s genomic tests across its hospitals.
The partnership in gene-based diagnostics with the Bangalore-based healthcare research company will help doctors at Apollo to develop personalised medicine for targeted treatments and better patient outcomes.
The Johns Hopkins University has joined the National Science Foundation’s National Innovation Network and becomes the fourth member university in the NSF Innovation Corps regional collaboration led by the University of Maryland, along with the George Washington University and Virginia Tech.
The NSF has approved a request from the three original universities to officially include Johns Hopkins in the I-Corps program’s “node” in the Mid-Atlantic called DC I-Corps, which was formed last year with $3.75 million in NSF funding.
PRESENTERS: Konstantina Manjoros Katcheves, Esq., Vice President and Global Head of Intellectual Property, Lonza Group, Ltd.
ABSTRACT:
Lonza Group Ltd., headquartered in Basel, Switzerland, is a worldwide leader in supplying the pharmaceutical and biotechnology industries with biopharmaceuticals. Come to learn first-hand how you can partner and collaborate with this international firm and develop a win-win relationship with Lonza.
Biography:
Konstantina Manjoros Katcheves, Esq. As global head of the intellectual property department at Lonza, Tina is responsible for patent, trademark and licensing strategy as well as related litigation. She manages a worldwide team of professionals for the Basel, Switzerland-based pharmaceutical company. She is responsible for intellectual property strategy and business alignment including patent, trademark and licensing of Lonza IP for Lonza’s Biologics businesses, including cell therapy and antibody therapeutics.
Tina has past experience in private practice, as a USPTO examinerand registered patent attorney. She is an author and speaker on a wide variety of topics including intellectual property and commercialization.
Eight startup companies are among 67 recipients of Maryland Innovation Initiative awards in fiscal 2014.
The Maryland Innovation Initiative gave a total of $6.4 million to research projects and startups with ties to universities in the state. The innovation initiative is designed to spur commercialization of university research.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notice:
Request for Information: Shared Instrumentation Grant Program (S10) (NOT-OD-14-104) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Extramural Loan Repayment Program for Clinical Researchers (LRP-CR) (NOT-OD-14-105) National Institutes of Health
Extramural Clinical Research Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (LRP-IDB) (NOT-OD-14-106) National Institutes of Health
Extramural Loan Repayment Program for Pediatric Research (LRP-PR) (NOT-OD-14-107) National Institutes of Health
Extramural Loan Repayment Program for Contraception and Infertility Research (LRP-CIR) (NOT-OD-14-108) National Institutes of Health
Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR) (NOT-OD-14-109) National Institutes of Health
Notice of the National Institute on Deafness and Other Communication Disorders (NIDCD) Participation in PA-14-114 “Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)” (NOT-DC-14-003) National Institute on Deafness and Other Communication Disorders
Notice of Change to the Award Budget and Submission Requirements for PAR-12-198 “Improving Diet and Physical Activity Assessment (R01)” (NOT-DK-14-023) National Institute of Diabetes and Digestive and Kidney Diseases
Notice of NICHDs Participation in PAR-13-055 “Dissemination and Implementation Research in Health (R01)” (NOT-HD-14-017) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Request for Information: NHLBI Whole Genome Sequencing Project (NHLBI-WGS) (NOT-HL-14-030) National Heart, Lung, and Blood Institute
Notice of the Change in the Expiration Date for PA-11-347 “NINDS SBIR Technology Transfer (SBIR-TT [R43/R44])” (NOT-NS-14-038) National Institute of Neurological Disorders and Stroke
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Jennifer Hammaker has watched biotech company respEQ Inc. grow from an experiment in a Johns Hopkins lab to a fledgling startup now looking for investors.
RespEQ is a prime example of what Hammaker, who leads the Maryland Innovation Initiative, hopes the state’s research commercialization program will produce more of in the future.
The startup world will perk up to hear that RockthePost and CoFoundersLab recently merged to form Onevest. Together the two companies will provide a single source for startup founders to not only find investors but also find the right co-founders all online.
Kaiser is well known healthcare delivery model and outcomes, but, it turns out, it’s also among the best at engaging members via the web and mobile apps. The organization says in its 2013 annual report (just released) that about 4.4 million of its 9.1 million members use its online health management platform My Health Manager.
It helps to have a friend. And for several pharma giants scrambling to cut R&D costs, those friends are venture capital firms that co-invest in startups whose new drugs and platform technologies appear attractive. In some cases, these pharma-venture “alliances” launch the startups, using the expertise of VC firm partners and company executives.
He’s pointing out a challenge for entrepreneurs, not griping. He’s lived in California, Boston and New York, and he chose this area for a reason — “Maryland-D.C. is the mecca of security.”
So far, the bet’s paid off. ZeroFOX, which focuses on cybersecurity threats from social media, has raised $13 million from both local and out-of-state investors. Among them is Sourcefire’s former chief financial officer. That’s allowed the company to expand from its original two people to nearly 50.
Like its business incubators for technology, cybersecurity and biotech, Montgomery County hopes a kitchen incubator will help food entrepreneurs thrive in the county.
The county is seeking proposals for a private partner to help “accelerate the commercialization of creations from local food entrepreneurs” by establishing a kitchen incubator, a shared kitchen space food entrepreneurs can use to start their businesses.
There is clearly something wrong with pharmaceutical innovation.
Antibiotic-resistant infections sicken more than two million Americans every year and kill at least 23,000. The World Health Organization has warned that a “post-antibiotic era” may be upon us, when “common infections and minor injuries can kill.” Even the world’s tycoons consider the proliferation of antibiotic-resistant bacteria one of the crucial global risks of our times, according to a survey by the World Economic Forum.
NextNav LLC, the bicoastal location services venture launched by XM Satellite Radio founder Gary Parsons, announced on Thursday a $70 million Series D funding led by New Enterprise Associates and Oak Investment Partners.
The eight-figure round is the latest high-dollar financing for NextNav, which two years ago reported a $50 million raise from Columbia Capital. Columbia also joined in the most recent round, alongside Telcom Ventures and Goldman Sachs Investment Partners.
On Thursday, July 17, four science experts served as witnesses at the U.S. Senate Committee on Commerce, Science, and Transportation hearing, “The Federal Research Portfolio: Capitalizing on Investments in R&D.” The hearing considered the federal government’s role in research and development (R&D), and the nation’s STEM education and outreach initiatives.
Attendees in the Capitol hearing room were Mariette DiChristina, editor in chief and senior vice president of Scientific American; Vinton G. Cerf, computer scientist, Google’s Internet Evangelist and one of the fathers of the Internet; Neal F. Lane, former director of the White House Office of Science and Technology Policy; and Stephen E. Fienberg, professor of statistics and social science at Carnegie Mellon University.
Maryland companies raised $64 million in venture capital funding this spring, with some of the biggest payouts flowing to Baltimore cybersecurity startups.
That’s according to the latest MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Association. The report, which uses Thomson Reuters data, tracks money flowing to startups and later-stage firms across the country.
Founders Fund already stands out for backing startups with radical ideas, including Counsyl, Hampton Creek, Planet Labs, and SpaceX. Now the venture firm is making a formal commitment to funding startups in aeronautics, life sciences, nanotechnology, and other geeky realms. Founders Fund has dedicated a small percentage of its new $1 billion fund to a new initiative called FF Science, through which the firm will make seed-stage deals.
While considerable attention has been heaped on the public health insurance exchanges over the year, private health insurance exchanges “are experiencing hyper-growth” and enrollment could exceed that of public exchanges by 2017, “if not sooner,” according to Accenture.
After decades as a technological laggard, medicine has entered its data age. Mobile technologies, sensors, genome sequencing, and advances in analytic software now make it possible to capture vast amounts of information about our individual makeup and the environment around us. The sum of this information could transform medicine, turning a field aimed at treating the average patient into one that’s customized to each person while shifting more control and responsibility from doctors to patients.
The question is: can big data make health care better?
Capital efficiency has become a mantra at Atlas, one shared by a number of other early stage biotech investors. It’s a term often repeated in discussions about building young companies, and yet it has become clear that there’s no consistent definition of what the term means.
A common perception is that capital efficiency is synonymous with tightly constrained, small amounts of investor capital – the “small ball” criticism of capital efficiency. Others think it means only ultra-lean, asset-centric, virtual companies. There’s also the perception that you can’t build something big if you are capital efficient.
In 1957, eight entrepreneurs decided to do something that seemed crazy. They launched a new tech company called Fairchild Semiconductor in a small town south of San Francisco. The entrepreneurs had a difficult start, but Fairchild eventually became the first major computer chip company in the region.
The BioMaryland Center today joined with Medicen Paris Region to announce a co-funded international project to support commercialization and collaboration in their two regions. Opticul Diagnostics of Rockville, Md. and Diafir of Rennes, France have been selected as the first two participants of a partnership that was created at BIO International 2012 to promote collaboration on products to improve and speed diagnoses and patient care. The announcement was made at the BIO International Convention 2014 in San Diego.
This is the first jointly funded international project undertaken by the BioMaryland Center, which is part of the Department of Business and Economic Development (DBED) of Maryland. The state of Maryland is the fourth largest biopharma concentration in the United States and Medicen Paris Region represents one of Europe’s largest clusters of life science and health care companies.
It’s not unusual for hospitals to have innovation centers these days, but the folks at New York Presbyterian Hospital have chosen an interesting satellite office for theirs: in the offices that house health IT accelerator Blueprint Health. It’s a remarkable development for an industry in which hospitals have tended to hold startups at arm’s length.
Although hospitals and health systems often welcome entrepreneurs’ motivation to improve healthcare, their knack for identifying problems and developing solutions as well as using technology to speed up care delivery, the complexities of making startup solutions work in healthcare has been challenging. Providers are frequently frustrated by an insufficient understanding by startups of hospital workflows, the complexities of implementing new technology along with the safety and regulatory rigors involved. On the flipside, healthcare startups are often frustrated by what they perceive as the snail-like pace of hospitals to adopt new health IT tools and make care delivery more efficient.
More than 80% of U.S. consumers conduct online research prior to making everyday purchases. This is a statistic that is growing, and extends beyond products to include services and, finally, even healthcare. With the abundance of information available, consumers are empowered–they want to be as informed as possible when selecting physicians, but how does someone navigate through the overwhelming results of Google searches and decide how to best make a decision as important as selecting a healthcare provider? I think most people would agree that selecting a physician and selecting where to have dinner have highly differing degrees of importance when it comes to online research.
There’s a panoply of alternative funding streams for healthcare startups out there – fledgling companies are seeking out avenues like prepaid revenue models, grant funding in lieu of venture capital, and the ever-popular crowdfunding approach.
The outcomes can be a mixed bag, however, said a panel of speakers at MedCity News’ CONVERGE conference in Philadelphia today.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds under development that target the SF3B1 gene.
Inside sources reveal that Indian pharmaceutical generics firm Lupin, along with other U.S. pharma firms, is considering bidding for GlaxoSmithKline’s auctioned mature and generic drugs.
Montgomery County plans to launch a major technology initiative in its public schools in August, providing 40,000 laptops and tablets to students as part of a project that will expand quickly in coming years, officials said Thursday.
Infectious diseases, pathogens and bioterrorism agents are all inside a new building downtown. Jessica Kartalija explains it’s great news for researchers at Johns Hopkins. It’s the newest addition to the Baltimore Science and Technology Park at Johns Hopkins. Inside, it’s a state-of-the-art lab that will keep Maryland on the cutting edge of public health and technology.
The Intellectual Property Owners (IPO) recently published a list of the top 100 universities worldwide granted U.S. patents in 2013, and among them were three local schools: Johns Hopkins University, the University of Maryland and the University of Virginia.
Jennifer Hammaker has watched biotech company respEQ Inc. grow from an experiment in a Johns Hopkins lab to a fledgling startup now looking for investors.
The startup world will perk up to hear that RockthePost and CoFoundersLab recently merged to form Onevest. Together the two companies will provide a single source for startup founders to not only find investors but also find the right co-founders all online.
Kaiser is well known healthcare delivery model and outcomes, but, it turns out, it’s also among the best at engaging members via the web and mobile apps. The organization says in its 2013 annual report (just released) that about 4.4 million of its 9.1 million members use its online health management platform My Health Manager.
It helps to have a friend. And for several pharma giants scrambling to cut R&D costs, those friends are venture capital firms that co-invest in startups whose new drugs and platform technologies appear attractive. In some cases, these pharma-venture “alliances” launch the startups, using the expertise of VC firm partners and company executives.
Founders Fund already stands out for backing startups with radical ideas, including Counsyl, Hampton Creek, Planet Labs, and SpaceX. Now the venture firm is making a formal commitment to funding startups in aeronautics, life sciences, nanotechnology, and other geeky realms. Founders Fund has dedicated a small percentage of its new $1 billion fund to a new initiative called FF Science, through which the firm will make seed-stage deals.
While considerable attention has been heaped on the public health insurance exchanges over the year, private health insurance exchanges “are experiencing hyper-growth” and enrollment could exceed that of public exchanges by 2017, “if not sooner,” according to Accenture.
In 1957, eight entrepreneurs decided to do something that seemed crazy. They launched a new tech company called Fairchild Semiconductor in a small town south of San Francisco. The entrepreneurs had a difficult start, but Fairchild eventually became the first major computer chip company in the region.
